Form 4: Moderna CEO Bancel Exercises $13.5M Stock Options

Moderna CEO Stephane Bancel exercised stock options to acquire 688,073 shares of common stock, paying over $13.4 million in cash.

Summary

• Stephane Bancel, CEO and Director of Moderna, Inc., exercised stock options to acquire 688,073 shares of the company's common stock.
• The transaction occurred on December 11, 2025, with an exercise price of $10.90 per share.
• Bancel paid a total of $7,499,995.70 for the exercise price and an additional $5,998,279.76 for applicable withholding taxes, totaling $13,498,275.46 in cash.
• No shares of Moderna were sold or withheld in connection with this exercise.
• The exercised option was fully vested and would have expired on February 23, 2026, if not exercised.
• Following the transaction, Bancel directly owns 6,181,970 shares of common stock.
• He also has indirect beneficial ownership of 9,210,686 shares through Boston Biotech Ventures and 6,564,880 shares through OCHA LLC, disclaiming Section 16 beneficial ownership except for his pecuniary interest.

Sentiment

Score: 7

Explanation: The CEO's exercise of a significant number of stock options, coupled with a substantial cash outlay and no immediate sale of shares, indicates strong confidence in the company's future performance and aligns executive interests with shareholders.

Positives

• CEO Stephane Bancel demonstrated confidence in Moderna by exercising a significant number of stock options and paying a substantial cash amount ($13,498,275.46) without selling any shares.
• The exercise prevented the forfeiture of 688,073 options that were set to expire on February 23, 2026.
• Increased direct beneficial ownership by a key executive aligns management's interests with shareholders.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Management Comments

• The filing does not contain direct quotes or paraphrased statements from company management, beyond the factual reporting of the transaction.

Industry Context

This insider transaction reflects a standard executive compensation event within the biotechnology and pharmaceutical industry, where stock options are a common component of executive pay. The exercise of options, particularly when nearing expiration and without an immediate sale, can be interpreted as a sign of continued confidence in the company's long-term prospects, which is a common sentiment observed among executives in growth-oriented sectors like biotech.

Comparison to Industry Standards

• This transaction is a routine insider filing for an executive exercising stock options. It aligns with common practices in the biotechnology sector where executives often exercise options as they approach expiration to avoid forfeiture and increase their direct equity stake.
• There are no specific comparable companies or projects mentioned in the filing to benchmark against, as it solely reports an individual's equity transaction.

Related Party Transactions

• The filing mentions indirect beneficial ownership through Boston Biotech Ventures (9,210,686 shares) and OCHA LLC (6,564,880 shares), where the reporting person disclaims Section 16 beneficial ownership except for pecuniary interest. These are existing ownership structures, not new transactions.

Stakeholder Impact

• Shareholders: The transaction could be viewed positively by shareholders as it signals insider confidence and increased alignment of the CEO's interests with the company's long-term success.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Key Dates

Recommendation

The filing reports a routine insider transaction where the CEO exercised stock options nearing expiration. While it demonstrates insider confidence by increasing direct ownership without selling shares, it does not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should hold and continue to monitor broader company performance and market conditions.

Keywords

Moderna, MRNA, Stephane Bancel, CEO, Director, Stock Option, Exercise, Insider Transaction, Common Stock, Equity, Beneficial Ownership, SEC Form 4